References

1. Qaddoumi I, Sultan I, Gajjar A: Outcome and Prognostic Features in Pediatric Gliomas: a Review of 6212 Cases From the SEER Database. Cancer 115: 5761-5770, 2009. 2. Ochroch EA, Fleisher LA: Evaluating pediatric spinal low-grade gliomas—a 30-year retrospective analysis. Anesthesiology 105: 643-644, 2019. 3. Fussey JM, Vaidya B, Kim D, Clark J, Ellard S, Smith JA: The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: A systematic review. Clin Endocrinol (Oxf) 91: 697-707, 2019. 4. Soiza RL, Donaldson AIC, Myint PK: Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Vaccines 9: 259-261, 2018. 5. Chen DS, Mellman I: Elements of cancer immunity and the cancer-immune set point. Nature 541: 321-330, 2017. 6. Herbst RS, Morgensztern D, Boshoff C: The biology and management of non-small cell lung cancer. Nature 553: 446-454, 2018. 7. Jørgensen JT: A paradigm shift in biomarker guided oncology drug development. Ann Transl Med 7: 148, 2019. 8. Rubin JB, Segal RA: Growth, survival and migration: the Trk to cancer. Cancer Treat Res 115: 1-18, 2003. 9. Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, et al: Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 19: 705-714, 2018. 10. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. N Engl J Med 378: 731-739, 2018. 11. Zhao X, Kotch C, Fox E, Surrey LF, Wertheim GB: NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome. J Clin Oncol 37: 1234-1242, 2019. 12. Nakagawara A: Trk receptor tyrosine kinases: A bridge between cancer and neural development. Cancer Lett 169: 107-114, 2001. 13. Amatu A, Sartore-Bianchi A, Siena S: NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 1: e000142, 2016. 14. Torre M, Vasudevaraja V, Serrano J, Delorenzo M, Malinowski S, Blandin AF, et al: Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathol Commun 8: 1-14, 2020. 15. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R: Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol 2: 1-20, 2018. 16. Johnson K, Barragan J, Bashiruddin S, Smith CJ, Tyrrell C, Parsons MJ, et al: TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Physiol Behav 176: 139-148, 2017. 17. Ferguson SD, Zhou S, Huse JT, De Groot JF, Xiu J, Subramaniam DS, et al: Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. Mol Cancer Res 18: 512-521, 2020. 18. Gatalica Z, Xiu J, Swensen J, Vranic S: Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 32: 147-153, 2019. 19. Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, et al: NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 33: 38-46, 2020. 20. Yoshihara K, Wang Q, Torres-garcia W, Zheng S, Vegesna R, Kim H, et al: The landscape and therapeutic relevance of cancer-associated transcript fusions. J Clin Oncol 34: 4845-4854, 2016. 21. DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, et al: The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer 124: 4241-4247, 2018. 22. Deland L, Keane S, Olsson T, Sjögren H, Fagman H, Øra I: Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib. Cancer Biol Ther 22: 184-195, 2021. 23. Drilon A: TRK inhibitors in TRK fusion-positive cancers. Ann Oncol 30: VIII23-VIII30, 2019. 24. Gambella A, Senetta R, Collemi G, Vallero SG, Monticelli M, Cofano F, et al: NTRK fusions in central nervous system tumors: A rare, but worthy target. Int J Mol Sci 21: 1-24, 2020. 25. Adela M, Ales V, Petr B, Katerina V, David S, Lucie S, et al: Integrated genomic analysis reveals actionable targets in pediatric spinal cord low-grade gliomas. Acta Neuropathol Commun 10: 1-11, 2022. 26. Range K, MD, Moser YA: TRKing down an old oncogene in a new era of targeted therapy. Bone 23: 1-7, 2012. 27. Avinash K, Thakar S, Aryan S, Ghosal N, Hegde A: Malignant Transformation of Pediatric Low-grade Gliomas: Report of Two Cases and Review of a Rare Pathological Phenomenon. Neurol India 67: 1100-1106, 2019. 28. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. N Engl J Med 378: 731-739, 2018.